United States Patent 10,047,141: What the Claims Cover, Where They Read on the Market, and How the Landscape Likely Shapes Enforcement

US Patent 10,047,141 claims a narrow, process-specific method for producing TNFR-Fc and anti-TNF antibodies (and listed therapeutic antibodies including etanercept, adalimumab, infliximab) in CHO-based perfusion using a low total amino acid (TAA) feed medium, with defined concentration bands and performance criteria (protein titer threshold). The enforceable core is not “perfusion,” but perfusion plus a specific feed chemistry window (TAA <70 mM in the broadest method claim; 15 to 65 mM with specified co-components in the independent perfusion claim) plus a minimum protein titer requirement (at least 300 µg/mL).

What is the legal claim architecture of US 10,047,141?

Independent claims

Claim 1 (method manufacturing; perfusion + TAA threshold + titer + target molecule type)

Produces a protein via perfusion
Uses feed medium comprising total amino acid concentration < 70 mM
Achieves protein titer ≥ 300 µg/mL
Protein is TNFR-Fc fusion protein or an anti-TNF antibody

Claim 10 (perfuse method; tighter feed definition + CHO + perfusion operations + titer + target molecule type)

Prepares mixture: CHO cells + culture medium
Vessel production with periodic or continuous removal of spent medium and addition of fresh medium (classic perfusion)
Culture medium comprises:
- TAA concentration 15 to 65 mM
- At least one selected from: complex chemically-defined feed, dexamethasone, ManNAc, cottonseed hydrolysate, D-(+)-galactose
Achieves protein titer ≥ 300 µg/mL
Therapeutic protein is TNFR-Fc fusion protein or anti-TNF antibody

Dependent claim “slicers” (subclassifying cell type, temperature windows, feed components, and target proteins)

Key dependent elements:

Claim 2: enumerates TAA ranges in bands: 15-20, 20-25, …, 65-70 mM (selected from the list).
Claims 3 and 9: restrict target selection to etanercept, adalimumab, infliximab, or a biosimilar.
Claim 4: requires one or more of base medium, cottonseed hydrolysate, dexamethasone, ManNAc, D-(+)-galactose.
Claims 5-8: introduce pre-production growth phase at defined temperatures and define production temperatures in multiple selectable bins and thresholds (e.g., >32°C; >34°C; >35°C; ranges such as 33-36°C; 35-36°C; and specific points 32.5°C, 33.5°C, 34.5°C, 35.5°C).
Claims 12-14: specialize to etanercept (or biosimilar) and apply the same temperature window logic.

Practical reading: US 10,047,141’s claim set is a “process parameter lattice.” The most enforceable hooks are (i) the TAA concentration window and (ii) the perfusion + titer outcome tied to TNFR-Fc/anti-TNF therapeutic product types. Temperature and listed feed adjuncts are secondary hooks that strengthen specificity and help distinguish from prior perfusion systems that use different nutrient strategies.

What exactly do the claims require for infringement (technical elements checklist)?

For Claim 1, an accused process must match all of the following elements:

Perfusion production of a protein
Feed medium contains TAA < 70 mM
Protein titer ≥ 300 µg/mL is achieved in the production step
The protein is a TNFR-Fc fusion protein or an anti-TNF antibody

For Claim 10, infringement requires a stricter alignment:

CHO cells capable of expressing the protein
Production in a vessel with periodic or continuous media exchange (spent removal + fresh addition)
Culture medium satisfies:
- TAA 15 to 65 mM
- and includes at least one of: complex chemically-defined feed, dexamethasone, ManNAc, cottonseed hydrolysate, D-(+)-galactose
Titer ≥ 300 µg/mL
Protein is TNFR-Fc or anti-TNF antibody

Dependent claims then narrow further, but the independent claims define the main infringement surface.

How narrow is the TAA framing, and why it matters?

The claim drafting ties novelty and/or patentability to a low-to-moderate amino acid regime:

Claim 1: TAA < 70 mM
Claim 10: TAA 15 to 65 mM

This matters because many industrial fed-batch and perfusion formulations operate with amino acid loads that can be substantially higher than 65 mM once concentrated supplements are used, or they rely on different nutrient schemes where TAA is not the controlling parameter (e.g., maintaining osmolality, glucose, or lactate targets while amino acids float based on upstream metabolism and supplementation strategy). The patent’s performance tie (≥300 µg/mL) attempts to prevent “paper” nutrient-window overlap without corresponding productivity.

Selected bands explicitly enumerated

Claim 2 creates discrete litigation-friendly options:

Dependent claim 2 option	TAA band (mM)
(a)	15 to 20
(b)	20 to 25
(c)	25 to 30
(d)	30 to 35
(e)	35 to 40
(f)	40 to 45
(g)	45 to 50
(h)	50 to 55
(i)	55 to 60
(j)	60 to 65
(k)	between 65 and 70

Performance criterion: “protein titer ≥ 300 µg/mL”

The claims anchor infringement to a measurable production outcome. For enforcement, “titer” and measurement context (harvest timing, sample normalization, unit interpretation) become central even if not explicitly defined in the excerpted claim text.

What products are covered, and what is the product-level risk profile?

The claims cover:

TNFR-Fc fusion proteins (etanercept is the emblematic example in the dependency set)
Anti-TNF antibodies
Specific embodiments via dependent claims:
- Etanercept
- Adalimumab
- Infliximab
- Biosimilars of the above

Risk implication: If a manufacturer produces these biologics in a perfusion CHO platform using a low amino acid feed and specific adjuncts (dexamethasone, ManNAc, cottonseed hydrolysate, or D-(+)-galactose), the claims map closely onto the likely process commonality across biosimilar manufacturers who iterate formulations for productivity and glycosylation control.

How do the feed-adjunct components broaden or constrain coverage?

Claim 10 requires at least one of five feed-adjunct types. That creates coverage flexibility: an accused process need not include all adjuncts. But it narrows the infringement path relative to a feed that only satisfies the TAA window.

Adjunct list in Claim 10:

Complex chemically-defined feed
Dexamethasone
ManNAc (N-acetylmannosamine)
Cottonseed hydrolysate
D-(+)-galactose

Claim 4 adds “one or more of the following,” including:

Base medium
cottonseed hydrolysate
dexamethasone
ManNAc
D-(+)-galactose

Practical reading: The adjunct language increases the chance that real-world perfusion processes can be argued as falling within the claim if they use these components for glycan or quality steering, because these additives are also present in some industry approaches to glycoform modulation (ManNAc and galactose) and stress/quality management (dexamethasone), though the precise mechanism and concentration are not stated in the excerpt.

Where does the temperature logic add defensibility, and where does it create a potential escape hatch?

Dependent claims 7-8 and 13-14 introduce growth and production temperature sets.

Growth phase temperature options (claims 7, 13)

28°C to 37°C
or 35°C to 36°C

Production phase temperature options (claims 8, 14)

Multiple selectable constraints:

Greater than 32°C
Greater than 34°C
Greater than 35°C
33°C to 36°C
35°C to 36°C
single points: 32.5°C, 33.5°C, 34.5°C, 35.5°C

Defensibility: Temperature-dependent productivity and quality behavior can differentiate a process from prior art perfusion methods that run at different temperature regimes or that use temperature shifts only for specific phases.

Escape-hatch risk for challengers: Because these are dependent claim elements, a process could avoid infringement of those dependent claims by not matching the listed temperature ranges, while still potentially infringing independent claims 1 or 10 if the core perfusion + TAA + titer + product type elements are met.

How strong is the “protein titer ≥ 300 µg/mL” constraint for novelty and enforcement?

The titer threshold acts as a performance limitation. For patent validity and enforcement:

It can support non-obviousness if prior art perfusion processes with low amino acid feeds did not reach that productivity threshold.
It also creates evidentiary burden for enforcement: proving that the accused process meets or exceeds the threshold under the claimed conditions.

In litigation posture terms: A defendant can focus invalidity or non-infringement efforts on the evidentiary coupling between nutrient concentration, perfusion mode, and the measured titer.

What is the patent landscape posture for such claims (likely prior art vectors)?

Without the full prosecution history and the cited references from US 10,047,141’s file wrapper, the landscape analysis necessarily focuses on the claim themes that typically appear in perfusion and biospecific antibody manufacturing prior art. The key vectors that often drive obviousness challenges here are:

Per-X (perfusion) methods in CHO for therapeutic proteins
- Perfusion systems in CHO are well established across decades, including periodic/continuous media exchange and cell retention devices.
- The claim attempts to distinguish via nutrient specification and productivity outcome.
Nutrient strategy and amino acid management in high productivity mammalian cultures
- “Low amino acid” approaches exist in mammalian culture literature; the novelty here is the specific quantified TAA bands combined with perfusion and a titer threshold.
Glycosylation modifiers used with CHO to adjust Fc glycans
- ManNAc and galactose derivatives are known tools for glycan modulation.
- Dexamethasone is used to improve productivity or quality attributes in some CHO contexts.
- Cottonseed hydrolysate is a complex supplement category that may appear in legacy media designs.
- The claims combine these adjuncts with a specific TAA window and perfusion.
TNFR-Fc and anti-TNF antibody production in perfusion
- Etanercept, adalimumab, infliximab biosimilar and reference manufacturing processes have extensive public disclosure from multiple sources, including regulatory filings and process development patents. The claim narrows by feed chemistry and titer.

Likely outcome for freedom-to-operate

The enforceable portion is narrow enough that a well-designed commercial process could avoid direct overlap by:

keeping the effective amino acid concentration above the claimed window, or
using different nutrient supplements not in the adjunct list, and/or
achieving high titers with a different perfusion nutrient framework.

But because Claim 1’s adjunct list is absent (it only requires TAA <70 mM and perfusion), it is more difficult to fully avoid infringement where TAA is genuinely controlled and remains below 70 mM.

How should portfolio strategists read this patent for acquisition, licensing, or challenge strategy?

If you are licensing or entering the TNFR/anti-TNF perfusion market

This patent is a “process claim block” that is most valuable for licensing when your manufacturing platform:

uses CHO perfusion,
targets TAA 15-65 mM or <70 mM in the relevant feed,
meets a titer ≥ 300 µg/mL performance threshold,
and either uses one or more of the adjuncts listed in Claim 10 or can be characterized as using them in the culture medium.

If you are defending against infringement

A defense path typically focuses on:

whether the effective total amino acid concentration is actually within the claimed window (feed formulation controls),
whether the measured titer meets the threshold under claimed production conditions,
whether the “culture medium” in your perfusion is characterized as including one of the specified adjuncts (for Claim 10), and
whether any additional dependent claim elements (temperature growth/production windows) match.

If you are challenging validity

For invalidity, the most potent arguments are usually built from:

prior perfusion CHO processes with strong productivity,
prior disclosure of amino-acid-restricted feeds (or TAA ranges),
prior disclosure of ManNAc/galactose/dexamethasone/cottonseed hydrolysate use in CHO antibody production,
combinations establishing predictable results in antibody manufacturing.

Claim 10’s “at least one selected from” adjunct phrasing can make combination arguments easier: an attacker needs only one adjunct overlap plus the amino-acid window and perfusion features.

Key tables for rapid claim mapping

Claim coverage map (elements to match)

Element	Claim 1	Claim 10
Production mode	Perfusion	Perfusion
Host cells specified	Not required	CHO required
TAA in feed	<70 mM	15-65 mM
Adjuncts required	Not required	At least one of 5 listed items
Titer threshold	≥300 µg/mL	≥300 µg/mL
Product type	TNFR-Fc or anti-TNF	TNFR-Fc or anti-TNF
Target examples via dependency	Etanercept/adali/inflix + biosimilar	Etanercept/adali/inflix + biosimilar (via dependencies)
Temperature constraints	via dependent claims	via dependent claims

“Adjacent coverage” through dependencies (what narrows further)

Dependency	Narrows to
Claim 2	Discrete TAA bands 15-20 through 65-70 mM
Claim 4	Base medium +/or cottonseed hydrolysate +/or dexamethasone +/or ManNAc +/or D-(+)-galactose
Claims 7-8	Growth and production temperature sets
Claims 12-14	Etanercept-specific variant with growth/production temperatures

Key Takeaways

US 10,047,141 is built around CHO perfusion antibody production with a specific total amino acid window and a minimum productivity threshold (titer ≥ 300 µg/mL).
The independent claims differ materially: Claim 1 is broader on adjunct chemistry (no adjunct list) but requires TAA <70 mM; Claim 10 is narrower and requires CHO plus a TAA 15-65 mM window and at least one specified feed adjunct.
Dependent temperature claims add enforcement leverage but also create a defensive non-infringement lever if an accused process does not match those specific temperature windows.
Product coverage is anchored in TNFR-Fc and anti-TNF therapeutics, with dependent claims listing etanercept, adalimumab, infliximab and biosimilars.

FAQs

1) What is the single most important quantitative parameter in US 10,047,141?
Total amino acid concentration: <70 mM in Claim 1 and 15-65 mM in Claim 10, coupled with protein titer ≥ 300 µg/mL.

2) Does the patent require ManNAc or galactose to infringe?
Not for Claim 1. Claim 10 requires at least one adjunct among complex chemically-defined feed, dexamethasone, ManNAc, cottonseed hydrolysate, or D-(+)-galactose.

3) Is CHO mandatory for all asserted embodiments?
CHO is mandatory for Claim 10. Claim 1 does not require CHO in the excerpted claim text.

4) Are etanercept, adalimumab, and infliximab explicitly covered?
They are explicitly listed in dependent claims as covered therapeutic proteins (and biosimilars), within the TNFR-Fc/anti-TNF scope.

5) What design choice most directly changes infringement risk for a perfusion process?
Keeping the effective feed amino acid composition and the achieved titer within or outside the claimed windows, and for Claim 10 specifically whether the culture medium includes at least one of the enumerated adjuncts.

References (APA)

[1] United States Patent and Trademark Office. US Patent 10,047,141 (claims as provided in the prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	⤷ Start Trial	2035-01-29
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	⤷ Start Trial	2035-01-29
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	⤷ Start Trial	2035-01-29
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	⤷ Start Trial	2035-01-29
Immunex Corporation	ENBREL	etanercept	Injection	103795	February 01, 2007	⤷ Start Trial	2035-01-29
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	September 14, 2017	⤷ Start Trial	2035-01-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,047,141

Summary for Patent: 10,047,141